ProQR Therapeutics: BofA initiates coverage with Buy, $8 target
BofA’s Alec Stranahan initiated coverage of ProQR Therapeutics with a Buy rating and a $8 price target, citing AX-0810 as first human validation of Axiomer and dose-dependent bile acid activity.